Modern H1- antihistamines in the treatment of allergic rhinitis: focus on bilastine

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The second generation of  H1-antihistamines  are approved for the stepwise treatmentof seasonal and perennial allergic rhinitis in adults and children by international and national guidelines. They reduce the severity of nasal and ocular symptoms of rhinitis  and improve the quality of life of patients.

Bilastine is a novel H1-antihistamines,  piperidine derivative. It has a potent and selective effect on H1- receptors, rapid onset and long duration of action, significantly reduces nasal and ocular symptoms of seasonal and perennial allergic rhinitis. Bilastine has not clinically significant hepatic metabolism and has a high safety profile (no sedation, no effect on cognitive functions, no cardiotoxicity, no interaction with alcohol and benzodiazepines in normal and high doses).  Tachyphylaxis does not develop during its long-term (up to 1 year) use.

Bilastine  is registered for clinical use in adults and children 12 years and older. The results of clinical and experimental studies evidence that bilastine has many of the features of modern H1-antihistamines, that are recommended  by international guidelines.

 

Full Text

Restricted Access

About the authors

Alexander V Emelyanov Emelyanov

Северо-Западный государственный медицинский университет им.И.И.Мечникова

Author for correspondence.
Email: emelav@inbox.ru
ORCID iD: 0000-0002-8574-6869

доктор медицинских наук, профессор, зав. кафедрой пульмонологии

Russian Federation

Galina Sergeeva

Email: sergreevagr@mail.ru
ORCID iD: 0000-0003-1544-4336

Evgenia Leshenkova

Email: leshenkova@mail.ru
ORCID iD: 0000-0003-4616-3166

References

  1. Bousquet J., van Cavuwenberge P., Khaltaev N. et al. Allergic rhinitis and its impact on asthma (ARIA)//J Allergy Clin Immunol. 2001; 108 (5), suppl: S.147-S.334 doi doi: 10.1067/mai.2001.118891
  2. Bousquet J, Schünemann HJ, Togias A, et al. Allergic Rhinitis and Its Impact on Asthma Working Group. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, De-velopment and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3. doi: 10.1016/j.jaci.2019.06.049.
  3. Papadopoulos N.G, Bernstein J.A, Demoly P. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report Allergy 2015; 70(5):474-94.doi: 10.1111/all.12573
  4. Bousquet PJ, Combescure C, Klossek JM, Daurès JP, Bousquet J. Change in visual ana-log scale score in a pragmatic randomized cluster trial of allergic rhinitis. J Allergy Clin Immunol. 2009; 123(6):1349-54. doi: 10.1016/j.jaci.2009.02.033.
  5. Eguiluz-Gracia I, Testera-Montes A, Rondon C. Medical algorithm: Diagnosis and treat-ment of local allergic rhinitis. Allergy. 2021;00:1–4 doi.org/10.1111/all.14848
  6. Ненашева Н.М., Шиленкова В.В. Контроль симптомов аллергического ринита у взрослых лиц в Российской Федерации: результаты онлайн-опроса. РМЖ «Меди-цинское обозрение» 2021; 51(1): 25-31 doi: 10.32364/2587-6821-2021-5-1-25-31
  7. Польнер СА. Федеральные клинические рекомендации: Аллергический ринит. Рос-сийский Аллергологический Журнал. 2017;14(2):47-54. doi.org/10.36691/RJA323
  8. Farre M., Perez-Manna C., Papaseit E et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy vol-unteers. Br J Clin Pharm 2014; 78 (5): 970-980 do: 10.1111/bcp.12421
  9. Church M.K. Maurer M., Simons FER et. Risk of first generation H1-antihistamines: a GAL2EN position paper. Allergy 2010; 65: 459-466 doi: 10.1111/j.1398-9995.2009.02325.x
  10. Simons F.E.R, Simons K.J. Histamine and H1-antihistamines: Celebrating a century of progress. J Allergy Clin Immunol 2011; 128:1139-1150 doi: 10.1016/j.jaci.2011.09.005
  11. Mizuguchi H, Wakugawa T, Sadakata H et al. Elucidation of Inverse Agonist Activity of Bilastine. Pharmaceutics. 2020;12(6):525. doi: 10.3390/pharmaceutics12060525.
  12. Church M.K., Tiongco-Recto M, Ridolo E., Novák Z. Bilastine: a lifetime companion for the treatment of allergies. Current Medical Research and Opinion, 2020 (36):3, 445-454, doi: 10.1080/03007995.2019.1681134
  13. Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D. 2005; 6(6):371-84. doi: 10.2165/00126839-200506060-00005
  14. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010; 59(5):391-8. doi: 10.1007/s00011-009-0117-4
  15. Garcıa-Gea C, Martınez J, Ballester MR, et al. Psychomotor and subjective effects of bi-lastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. Hum Psychopharmacol Clin Exp. 2014;29(2):120–132
  16. García-Gea С, Martínez-Colomer J, Antonijoan R, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 an-tihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008; (6):675-85. doi: 10.1097/JCP.0b013e31818b2091
  17. Valk PJ, Simons R, Jetten AM, Valiente R, Labeaga L. Cognitive Performance Effects of Bilastine 20 mg During 6 Hours at 8000 ft Cabin Altitude. Aerosp Med Hum Perform. 2016 Jul;87(7):622-7. doi: 10.3357/AMHP.4522.2016.
  18. Reményi A, Grósz A, Szabó S A et al, Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: a randomized, double-blind, placebo-controlled, cross-over study, Expert Opinion on Drug Safety 2018; 2018;17(9):859-868 doi: 10.1080/14740338.2018.1502268
  19. Tyl B., Kabbaj M., Azzam S et al. Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QTConcen-tration Analysis. J Clin Pharm 2013; 52(6): 893-903 doi: 10.1177/0091270011407191
  20. Graff C., Struijk J, Kanters J.K. et al. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Investig 2012;32(5):339-51. doi: 10.2165/11599270-000000000-00000.
  21. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R, Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009;39(9):1338-47. doi: 10.1111/j.1365-2222.2009.03257.x
  22. Bachert C, Kuna P, Sanquer F, Ivan P et al. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in sea-sonal allergic rhinitis patients. Allergy. 2009;64(1):158-65. doi: 10.1111/j.1398-9995.2008.01813.x.
  23. Sastre J, Mullol J, Valero A, Valiente R, Bilastine Study Group Collaborators. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treat-ment of perennial allergic rhinitis. Curr Med Res Opin. 2012 Jan;28(1):121-30. doi: 10.1185/03007995.2011.640667.
  24. Okubo K, Gotoh M, Asako M, Nomura Y, Togawa M, Saito A, Honda T, Ohashi Y. Ef-ficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A mul-ticenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergol Int. 2017;66(1):97-105. doi: 10.1016/j.alit.2016.05.014
  25. Okubo K, Gotoh M, Togawa M, Saito A, Ohashi Y. Long-term safety and efficacy of bi-lastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with aller-gic rhinitis: Results of an open-label trial. Auris Nasus Larynx. 2017;44(3):294-301. doi: 10.1016/j.anl.2016.07.021.
  26. Novák Z, Yáñez A., Kiss I., Kuna P., Tortajada-Girbés M., Valiente R., “Bilastine Paedi-atric Safety Study Group”. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol. 2016; 27(5):493-8. doi: 10.1111/pai.12555.
  27. Camelo-Nunes IC, Sol_e D. Allergic rhinitis: indicators of quality of life. J Bras Pneu-mol. 2010;36(1):124–133. doi: 10.1590/s1806-37132010000100017.
  28. Kirmaz C, Aydemir O, Bayrak P, et al. Sexual dysfunction in patients with allergic rhi-noconjunctivitis. Ann Allergy Asthma Immunol. 2005;95(6):525–529. doi: 10.1016/S1081-1206(10)61013-7.
  29. Locks RB, Dos Santos K, da Silva J. Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine. Clin Otolaryngol. 2017;42(2):218–224. doi: 10.1111/coa.12695.
  30. Jauregui I, Bartra J, del Cuvillo A, et al. Bilastine and quality of life. J Investig Allergol Clin Immunol. 2011;21(Suppl 3):16–23.
  31. Montoro J, Mullol J, D_avila I, et al. Bilastine and the central nervous system. J Investig Allergol Clin Immunol. 2011;21 (3):9–15.
  32. Vozmediano V, Sologuren A, Lukas JC, et al. Model informed pediatric development applied to bilastine: ontogenic pk model development, dose selection for first time in children and PK study design. Pharm Res. 2017;34(12):2720–2734. doi: 10.1007/s11095-017-2248-6
  33. Vozmediano V, Lukas JC, Encinas E, et al. Model-informed pediatric development ap-plied to bilastine: analysis of the clinical PK data and confirmation of the dose selected for the target population. Eur J Pharm Sci. 2019;128: 180–192 doi: 10.1016/j.ejps.2018.11.016
  34. Bilastine 10mg orodispersible tablets: summary of product characteristics;
  35. [cited 2021 May 24]. Available from: http://www. gov.uk/pil-spc.
  36. Bilastine 2.5 mg/ml oral solution: summary of product characteristics; 2018 [cited 2021 May 24]. Available from: http://www.gov.uk/pil-spc.
  37. Demoly P, Chiriac AM, Berge B, Rostin M. Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response. Aller-gy, Asthma & Clinical Immunology 2014; 10:29. doi: 10.1186/1710-1492-10-29
  38. Demoly P, Aubier M, de Blay F, Wessel F, Clerson P, Maigret P. Evaluation of patients’ expectations and benefits in the treatment of allergic rhinitis with a new tool: the patient benefit index – the benefica study. Allergy Asthma Clin Immunol. 2015; 11(1): 8. doi: 10.1186/s13223-015-0073-1
  39. Lynde CW , Sussman G,B Dion P.L. et al Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine. J Drugs Dermatol. 2020;19(2):145-154. doi: 10.36849/JDD.2020.4835

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract: 26

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) Russian Journal of Allergy

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies